219 related articles for article (PubMed ID: 24276119)
1. NMDA Receptor Antagonists for Treatment of Depression.
Ates-Alagoz Z; Adejare A
Pharmaceuticals (Basel); 2013 Apr; 6(4):480-99. PubMed ID: 24276119
[TBL] [Abstract][Full Text] [Related]
2. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.
Iadarola ND; Niciu MJ; Richards EM; Vande Voort JL; Ballard ED; Lundin NB; Nugent AC; Machado-Vieira R; Zarate CA
Ther Adv Chronic Dis; 2015 May; 6(3):97-114. PubMed ID: 25954495
[TBL] [Abstract][Full Text] [Related]
3. NMDA antagonists under investigation for the treatment of major depressive disorder.
Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice.
Fernandes A; Wojcik T; Baireddy P; Pieschl R; Newton A; Tian Y; Hong Y; Bristow L; Li YW
Eur J Pharmacol; 2015 Nov; 766():1-8. PubMed ID: 26325093
[TBL] [Abstract][Full Text] [Related]
5. An update on NMDA antagonists in depression.
Pochwat B; Nowak G; Szewczyk B
Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587
[No Abstract] [Full Text] [Related]
6. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.
Lauterbach EC
Med Hypotheses; 2012 Jun; 78(6):693-702. PubMed ID: 22401777
[TBL] [Abstract][Full Text] [Related]
7. Ketamine, but not MK-801, produces antidepressant-like effects in rats responding on a differential-reinforcement-of-low-rate operant schedule.
Hillhouse TM; Porter JH
Behav Pharmacol; 2014 Feb; 25(1):80-91. PubMed ID: 24370559
[TBL] [Abstract][Full Text] [Related]
8. Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery.
Musazzi L
Expert Opin Drug Discov; 2021 Feb; 16(2):147-157. PubMed ID: 32962432
[TBL] [Abstract][Full Text] [Related]
9. Effects of ifenprodil on the antidepressant-like activity of NMDA ligands in the forced swim test in mice.
Poleszak E; Wośko S; Serefko A; Szopa A; Wlaź A; Szewczyk B; Nowak G; Wlaź P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():29-35. PubMed ID: 23774195
[TBL] [Abstract][Full Text] [Related]
10. Investigational NMDA receptor modulators for depression.
Szewczyk B; Pałucha-Poniewiera A; Poleszak E; Pilc A; Nowak G
Expert Opin Investig Drugs; 2012 Jan; 21(1):91-102. PubMed ID: 22097925
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats.
Tizabi Y; Bhatti BH; Manaye KF; Das JR; Akinfiresoye L
Neuroscience; 2012 Jun; 213():72-80. PubMed ID: 22521815
[TBL] [Abstract][Full Text] [Related]
12. Lowered brain stimulation reward thresholds in rats treated with a combination of caffeine and N-methyl-D-aspartate but not alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate or metabotropic glutamate receptor-5 receptor antagonists.
Bespalov A; Dravolina O; Belozertseva I; Adamcio B; Zvartau E
Behav Pharmacol; 2006 Jun; 17(4):295-302. PubMed ID: 16914947
[TBL] [Abstract][Full Text] [Related]
13. A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice.
Zanos P; Nelson ME; Highland JN; Krimmel SR; Georgiou P; Gould TD; Thompson SM
eNeuro; 2017; 4(1):. PubMed ID: 28275719
[TBL] [Abstract][Full Text] [Related]
14. The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.
Zanos P; Piantadosi SC; Wu HQ; Pribut HJ; Dell MJ; Can A; Snodgrass HR; Zarate CA; Schwarcz R; Gould TD
J Pharmacol Exp Ther; 2015 Oct; 355(1):76-85. PubMed ID: 26265321
[TBL] [Abstract][Full Text] [Related]
15. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research.
Amidfar M; Woelfer M; Réus GZ; Quevedo J; Walter M; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109668. PubMed ID: 31207274
[TBL] [Abstract][Full Text] [Related]
16. Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine.
Löscher W; Hönack D
J Pharmacol Exp Ther; 1991 Feb; 256(2):432-40. PubMed ID: 1671593
[TBL] [Abstract][Full Text] [Related]
17. Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists.
Pozzi L; Pollak Dorocic I; Wang X; Carlén M; Meletis K
PLoS One; 2014; 9(1):e83879. PubMed ID: 24454710
[TBL] [Abstract][Full Text] [Related]
18. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression.
Serafini G; Pompili M; Innamorati M; Dwivedi Y; Brahmachari G; Girardi P
Curr Pharm Des; 2013; 19(10):1898-922. PubMed ID: 23173582
[TBL] [Abstract][Full Text] [Related]
20. Involvement of NMDA receptors in the antidepressant-like effect of tramadol in the mouse forced swimming test.
Ostadhadi S; Norouzi-Javidan A; Chamanara M; Akbarian R; Imran-Khan M; Ghasemi M; Dehpour AR
Brain Res Bull; 2017 Sep; 134():136-141. PubMed ID: 28754288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
